Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells
Authors Zhang L, Zhou Z, Wang Z, Du Y, He Z, Cao C, Zhou S
Received 14 July 2014
Accepted for publication 8 August 2014
Published 24 December 2014 Volume 2015:9 Pages 241—272
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Wei Duan
Li-Fang Zhang,1,2 Zhi-Wei Zhou,2 Zhen-Hai Wang,1 Yan-Hui Du,1 Zhi-Xu He,3 Chuanhai Cao,2 Shu-Feng Zhou2,3
1Department of Neurology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People’s Republic of China; 2Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA; 3Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, Guizhou, People’s Republic of China
Abstract: There is an increasing prevalence of Alzheimer’s disease (AD), which has become a public health issue. However, the underlying mechanisms for the pathogenesis of AD are not fully understood, and the current therapeutic drugs cannot produce acceptable efficacy in AD patients. Previous animal studies have shown that coffee (Coff), caffeine (Caff), and melatonin (Mel) have beneficial effects on AD. Disturbed circadian rhythms are observed in AD, and chronotherapy has shown promising effects on AD. In this study, we examined whether a combination of Coff or Caff plus Mel produced a synergistic/additive effect on amyloid-ß (Aß) generation in Neuro-2a (N2a)/amyloid precursor protein (APP) cells and the possible mechanisms involved. Cells were treated with Coff or Caff, with or without combined Mel, with three different chronological regimens. In regimen 1, cells were treated with Coff or Caff for 12 hours in the day, followed by Mel for 12 hours in the night. For regimen 2, cells were treated with Coff or Caff plus Mel for 24 hours, from 7 am to 7 am the next day. In regimen 3, cells were treated with Coff or Caff plus Mel with regimen 1 or 2 for 5 consecutive days. The extracellular Aβ40/42 and Aβ oligomer levels were determined using enzyme-linked immunosorbent assay (ELISA) kits. The expression and/or phosphorylation levels of glycogen synthase kinase 3β (GSK3β), Erk1/2, PI3K, Akt, Tau, Wnt3α, β-catenin, and Nrf2 were detected by Western blot assay. The results showed that regimen 1 produced an additive antiamyloidogenic effect with significantly reduced extracellular levels of Aβ40/42 and Aβ42 oligomers. Regimen 2 did not result in remarkable effects, and regimen 3 showed a less antiamyloidogenic effect compared to regimen 1. Coff or Caff, plus Mel reduced oxidative stress in N2a/APP cells via the Nrf2 pathway. Coff or Caff, plus Mel inhibited GSK3β, Akt, PI3K p55, and Tau phosphorylation but enhanced PI3K p85 and Erk1/2 phosphorylation in N2a/APP cells. Coff or Caff, plus Mel downregulated Wnt3α expression but upregulated β-catenin. However, Coff or Caff plus Mel did not significantly alter the production of T helper cell (Th)1-related interleukin (IL)-12 and interferon (IFN)-γ and Th2-related IL-4 and IL-10 in N2a/APP cells. The autophagy of cells was not affected by the combinations. Taken together, combination of Caff or Coff, before treatment with Mel elicits an additive antiamyloidogenic effects in N2a/APP cells, probably through inhibition of Aβ oligomerization and modulation of the Akt/GSK3β/Tau signaling pathway.
Keywords: Alzheimer’s disease, Aβ oligomer, coffee, caffeine, melatonin, Tau, Nrf2, chronotherapy, Akt
Alzheimer’s disease (AD) is a primary type of dementia (60%–80%) that is characterized by progressive loss of memory and cognition, brain atrophy, and accumulation of amyloid plaques and neurofibrillary tangles in the cortex, ultimately leading to complete debilitation and death.1,2 Typical clinical symptoms of AD include progressive short-term memory loss, impaired linguistic function, emotional dysfunction, impaired cognition, and dementia. AD can be further subdivided into early-onset (<65 years old, familial) and late-onset (>65 years old, sporadic) groups. Patients with either sporadic or familial AD share common clinical and neuropathological features.3,4 The Delphi study estimated that there were 24.3 million people with dementia in the world in 2001 and predicted that this would increase to 42.3 million in 2020 and 81.1 million by 2040.5 The countries or regions with the largest number of affected individuals are the People’s Republic of China and the developing Western Pacific, Western Europe, and the USA. There were about 25 million people with AD in 2010, and now nearly 36 million people have AD or a related dementia, worldwide.4,6 It is estimated that the number of AD patients will double every 5 years, and the number is expected to be 65.7 million in 2030 and 115.4 million worldwide in 2050 if we cannot find a cure. A recent meta-analysis based on 89 published reports has estimated that the number of people with AD increased from 1.9 million in 1990 to 5.7 million in 2010 in the People’s Republic of China.7 In the USA, an estimated 5.2 million Americans have AD in 2014 (ie, one in nine Americans over 65 has AD) and ~500,000 people die from AD each year, which makes AD the sixth leading cause of death.6,8,9 By 2050, it is expected that more than 13.8 million Americans will have AD. AD represents a major public health concern, and its increasing prevalence gives rise to a heavy burden to family and society.1,6,10,11 For example, the direct costs to American society of caring for those with AD will total an estimated $214 billion, including $150 billion in costs to Medicare ($113 billion) and Medicaid ($37 billion) in 2014.6 The global cost of AD and dementia is estimated to be $605 billion, which is equivalent to 1.0% of the entire world’s gross domestic product.12
The etiology of AD is not fully deciphered, and its pathogenesis is complicated. The most important risk factor for AD is age, and other AD risk factors include hypertension, stroke, heart diseases, depression, arthritis, type II diabetes, estrogen supplements, and smoking.1,2 There is a line of evidence that amyloid-β (Aβ) and the Tau protein play a key role in the development and progression of AD.1,13–17 Aβ peptides are proteolytic fragments of the transmembrane amyloid precursor protein (APP), whereas Tau is a brain-specific, axon-enriched microtubule-associated protein. APP is primarily processed by the aspartyl proteases β- and γ-secretase, and the β-secretase 1 (known as β-site APP cleaving enzyme 1 [BACE1], also named memapsin and Asp2) that is predominantly expressed in the brain as an integral membrane protein, with its carboxyl terminal end associated with the membrane in endosomes.18–20 In the nonamyloidogenic pathway, the a-secretase (ie, a disintegrin and metalloproteinase domain protein 10 [ADAM10]) prevents formation of toxic Aβ peptides from APP and alternatively catalyzes the formation of neuroprotective and neurotrophic soluble fragments (APPs-a) and membrane-bound fragment, C83.18–20 C83 is subsequently cleaved by the γ-secretase complex to yield the 3 kDa fragment, P3, and an APP intracellular domain. Accumulation of Aβ leads to plaque development, and hyperphosphorylation and aggregation of Tau protein, resulting in the formation of tangles.1,11–15 The behavioral symptoms of AD correlate with the aggregation of Aβ and phosphorylation level of Tau.17 Moreover, Aβ has been considered to be an upstream regulator of Tau in AD pathogenesis that triggers the conversion of Tau from a normal to a toxic status. On the other hand, it was shown that Tau enhanced Aβ toxicity via a feedback loop.1,11–15 Given the critical role of Aβ and Tau in the pathogenesis of AD, both Aβ- and Tau-associated pathways are the central targets for the development of new therapies aimed to ameliorate the development and progression of AD.15,21–23 To date, there is no cure for AD. Currently available therapeutic drugs for AD therapy approved by the US Food and Drug Administration include donepezil, galantamine, memantine, rivastigmine, and tacrine. Only memantine is an N-methyl-D-aspartate receptor antagonist, and the others are all cholinesterase inhibitors. These drugs are effective for about 6 to 12 months for about half of the patients who take them. However, these drugs have intrinsic limitations, including poor efficacy for chronic use and side effects.15,21–23 Therefore, there is an urgent need to develop novel therapeutic agents for the treatment of AD with improved outcomes and reduced side effects.
It has been recognized that coffee (Coff), caffeine (Caff) (1,3,7-trimethylxanthine or 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione) (Figure 1), and melatonin (Mel) (N-acetyl-5-methoxytryptamine) possess a variety of pharmacological activities, including antioxidative, antiapoptotic, antiautophagic, and neuroprotective effects.24 Caff is the most widely consumed psychoactive substance and acts as an antagonist of adenosine A1 receptors (A1Rs) and A2A receptors (A2ARs) at nontoxic doses.25 At high concentrations, Caff, like theophylline, acts as a nonselective phosphodiesterase inhibitor, thereby leading to higher levels of the intracellular second messenger cyclic adenosine monophosphate. Mel is synthesized mainly by the pineal gland during the dark phase of the circadian cycle and exhibits a number of physiological activities, including regulating circadian rhythms, inhibiting the oxidation of biomolecules and clearing free radicals, regulating intestinal motility and metabolism, and enhancing immunity.26,27 These effects are considered to be mediated by two specific Mel receptor subtypes, namely MT1 and MT2, which belong to G-protein-coupled receptors.28 MT1 receptors modulate neuronal firing, arterial contraction, and reproductive and metabolic functions, while MT2 receptors regulate circadian rhythms of neuronal firing in the suprachiasmatic nucleus, induce vasodilation, and enhance immune responses.27,28 Mel-mediated responses elicited by activation of MT1 and MT2 receptors depend on circadian time, duration, and mode of exposure to endogenous or exogenous Mel, and on functional receptor sensitivity. Studies show that Mel levels are significantly lower in AD patients compared with those in age-matched control subjects, and therefore, it is thought that a Mel deficit is closely associated with aging and age-related diseases, such as AD and Parkinson’s disease.29,30 Animal studies have shown that Coff, Caff, and Mel can prevent age-related cognitive impairment, delay the progression of AD, and ameliorate AD symptoms.31–34 Our previous studies also demonstrated that Mel improved mitochondrial function and directly bound to Aβ to inhibit Aβ aggregation in AD mice,35 and that there was a correlation between Caff/Coff intake and the risk of dementia or delayed onset.32,36,37 We have found that mild cognitive impairment patients with higher plasma Caff levels had delayed onset or lower risk of dementia during a 2–4 year follow-up period.37 Both Caff and Mel act as blockers of BACE1 and γ-secretase and thus, reduce Aβ production.37–39
Figure 1 Chemical structures of caffeine and melatonin.
Circadian rhythms are endogenously generated rhythms, with a periodicity of approximately 24 hours, that are driven by an endogenous circadian timekeeping system located in the suprachiasmatic nucleus of the hypothalamus.40–42 Circadian rhythms are generated as an output of the clock gene cycle, produced by a series of interlocking transcriptional feedback/feed forward loops of a series of clock genes (eg, PER1/2, CRY1.2, CLOCK, and BMAL1). Such cycles drive the rhythmic expression of clock-controlled genes, and ultimately, such molecular cycles are translated into physiological and behavioral circadian rhythms. Circadian rhythms have regulatory effects on cell proliferation, cell metabolism, cell senescence, and cell death, involving a number of functional proteins, such as cyclin D1 and sirtuin 1.25,26 Circadian dysfunction also impacts negatively on immune, metabolic, and cardiovascular systems.43,44 Notably, increasing evidence indicates that circadian rhythms play an important role in the pathogenesis of many ailments, including neurodegenerative diseases.41,45,46 It has been recognized that the circadian rhythms have a strong association with pharmacotherapeutic effects, so called “chronotherapy”.43,44,47 This refers to the administration of drugs at a certain time of day, resulting in the highest efficacy and the lowest side-effects, which profoundly influences the therapeutic outcomes in clinical settings.41 With circadian rhythms significantly disturbed in AD, they may have a direct link to the pathogenesis of AD, and accumulating evidence shows that chronotherapeutic approaches may generate benefits in the treatment of AD.46 Thus, more studies are needed to elucidate the role of circadian rhythms in the pathogenesis and therapy of AD.
To date, the effects of the combination of Coff or Caff and Mel on AD remain unclear, and the underlying mechanism for the beneficial effects of Coff, Caff, and Mel on AD is not fully understood. It has been suggested that reactive oxygen species (ROS), inflammation, and autophagy play a casual role in the development and progression of AD, with the involvement of glycogen synthase kinase 3β (GSK3β), Tau, and Wnt3α/β-catenin, resulting in Aβ accumulation and neuronal death.1,13,14,48–50 Therefore, we examined whether a combined use of Coff or Caff with Mel could give a synergistic or additive effect on Aβ generation in neurons via the regulation of ROS generation, inflammation, and autophagy.
Materials and methods
We employed the Discovery Studio program 3.1 designed by Accelrys Inc. (San Diego, CA, USA) to dock Caff and Mel into the active sites of ten human BACE1 structures (protein data bank [PDB] identification codes: 1FKN, 2OHU, 1W51, 2P4J, 2VKM, 4DH6, 3DV5, 2QU3, 3U6A, and 4FRS) as previously described by us.51–55 The crystal structure of human BACE1 was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/). Before defining and editing the binding site, BACE1 was cleaned, modified, and prepared. During the preparation for Caff and Mel, the duplicate structures were deleted, and ionization change, Tautomer or isomer generation, Lipinski filter, and three-dimensional (3D) generator were all set true. Following the ligand preparation, Caff and Mel were docked into the binding site of BACE1. Electrostatic energy and van der Waals forces were considered during the docking process. For each defined van der Waals force or electrostatic probe, the interactions with all protein atoms were stored at predetermined grid points. For ligand atoms located between grid points, a trilinear interpolation was used to approximate the energies. A harmonic potential with the force constant of 300 kcal/mol was applied outside the grid boundary.51–55
Chemicals and reagents
Caff and Mel were purchased from Sigma-Aldrich Corp (St Louis, MO, USA). Dulbecco’s Modified Eagle’s Medium (DMEM) was obtained from Corning Cellgro Inc. (Manassas, VA, USA). G418 (geneticin, a selective antibiotic), Dulbecco’s phosphate-buffered saline (PBS), 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), ethylenediaminetetraacetic acid (EDTA), and fetal bovine serum (FBS) were purchased from Sigma-Aldrich Corp. The autophagy detection kit was bought from Enzo Life Sciences Inc. (Farmingdale, NY, USA). Polyvinylidene difluoride (PVDF) membrane was purchased from EMD Millipore (Billerica, MA, USA). Western blot substrate was obtained from Thermo Fisher Scientific (Waltham, MA, USA). Primary antibodies against human Nrf2, LC3-I/II, Beclin 1, Wnt3α, β-catenin, phosphorylated (p)-Tau/Tau, p-GSK3β/GSK3β, p-Akt/Akt, p-PI3K/PI3K (p85/55), and p-Erk1/2/Erk1/2 were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). The antibody against human β-actin was obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).
Preparation of Coff, Caff, and Mel
Maxwell House® regular Coff (Kraft Foods, Northfield, IL, USA) was purchased commercially and dissolved in autoclaved water. Briefly, 40 g of ground Coff was added to 300 mL autoclaved water. Coff solution was then heated to boiling, kept at boiling for 2 minutes, then filtered with a Coff filter into an autoclaved container. The concentration of Coff was determined according to the content of Caff. The concentration of 10 μM Coff is equivalent to 10 μM Caff. For “unconcentrated” Coff solution, 1.5 mL aliquots (containing 1.5 mg/mL Caff) were transferred into 2 mL tubes and stored at −20°C. Caff (7 mg) was dissolved in 1 mL PBS, and the stock solution was stored at −20°C. Coff and Caff were freshly diluted to predetermined concentrations with medium before use. Mel (10 mg) was dissolved in 1 mL ethyl alcohol and diluted to 1, 5, and 10 μM with fresh medium before use (final ethyl alcohol concentration <0.01%, v/v). The chemical structures of Caff and Mel are shown in Figure 1.
Neuro-2a (N2a)/APP cells were derived from stably transfected N2a cells with Swedish mutant APPsw and were maintained in a DMEM supplemented with 10% FBS and 0.2 g/L G418 in 5% CO2 at 37°C.
We adopted three different chronological administration regimens in this study. N2a/APP cells were treated with Caff at 10 μM, 10 μM Coff (equivalent to 10 μM Caff), or Mel at 1, 5, or 10 μM alone or in combination. As shown in Figure 2, cells were treated with Coff or Caff at 10 μM for 12 hours in the day, followed by Mel at 1, 5, or 10 μM, for 12 hours in the night in regimen 1 (Figure 2). The medium was washed out after every 12-hour treatment. For regimen 2, cells were treated with Coff or Caff at 10 μM or Mel at 1, 5, and 10 μM, alone or in combination, for 24 hours, from 7 am to 7 am the next day. In regimen 3 (Figure 2), cells were treated with Coff or Caff or Mel for 5 consecutive days with regimen 1 or 2. N2a/APP cells were treated with Coff or Caff at 10 μM for 12 hours in the day, followed by Mel at 10 μM for 12 hours in the night and continued for 5 consecutive days. When regimen 2 was incorporated in regimen 3, the cells were treated with the drugs for 24 hours. The medium was changed at every 12- or 24-hour drug treatment.
Cell viability assay
The viability of N2a/APP cells was examined using the MTT assay. Briefly, the N2a/APP cells (8,000/well) were seeded into 96-well plates and treated with 10 μM Coff or Caff alone for 12 hours in the day, or with 1, 5, or 10 μM Mel for 12 hours in the night, or in combination. Following the treatment, 10 μL of MTT solution (5 mg/mL) was added to each well and incubated for 4 hours at 37°C. The medium was replaced with 100 μL dimethyl sulfoxide (DMSO), and the absorbance was measured using a Synergy™ H4 Hybrid Microplate Reader (BioTek Inc., Winooski, VT, USA) at a wavelength of 570 nm.
Enzyme-linked immunosorbent assay (ELISA)
The concentration of Aβ40/42 was measured using the Aβ40/42 Human ELISA kit (catalog number KHB3482/KHB3442; Life Technologies Corp, Carlsbad, CA, USA) according to the manufacturer’s instructions. The assay can recognize both natural and synthetic forms of human Aβ40/42, and the antibodies will not cross-react. According to the manufacturer’s instruction, we used the kits to measure the extracellular levels of Aβ in N2a/APP cells. The concentration of Aβ oligomer was measured using an Aggregated β-Amyloid Human ELISA kit (catalog number KHB3491; Life Technologies Corp) according to the manufacturer’s instructions. The culture medium was collected after N2a/APP cells were treated with indicated regimens. The samples were centrifuged at 100,000× g for 1 hour at 4°C prior to analysis. This oligomeric form of Aβ (also known as amyloid β−derived diffusible ligand [ADDL]) can be separated from fibrillar and protofibrillar forms of aggregated Aβ by high speed centrifugation (ie, 100,000× g for 1 hour) or by size exclusion methods, as previously described.56 Sample preparation should therefore be carefully considered when using this assay. Centrifugation at 14,000× g for 10 minutes has been shown to minimize fibrils in aggregated Aβ-containing samples, while centrifugation at 100,000× g for 1 hour at 4°C has been shown to minimize fibrils and protofibrils.56,57 Size exclusion methods, such as gel permeation chromatography or ultrafiltration, may also improve assay performance. The concentrations of interleukin (IL)-4, IL-12, and IL-10 were measured using ELISA kits (catalog number KHC0041/KHC0121/KAC1321; Life Technologies Corp). The concentration of interferon (IFN)-γ was determined using a Human IFN-γ ELISA Kit (catalog number EHIFNG; Thermo Fisher Scientific). The absorbance was detected at wavelength of 450 nm, using the Synergy™ H4 Hybrid Microplate Reader.
Western blot analysis
N2a/APP cells were washed with precooled PBS after treatment with indicated regimens and lysed with a lysis buffer consisting of 50 mmol HEPES at pH 7.5, 150 mmol NaCl, 10% glycerol, 1.5 mmol MgCl2, 1% Triton™ X-100, 1 mmol EDTA at pH 8.0, 10 mmol sodium pyrophosphate, 10 mmol sodium fluoride, and the protease inhibitor cocktail. The supernatant was collected after the cell lysate was centrifuged at 14,000× g for 15 minutes at 4°C. Protein concentrations were measured using the BCA Protein Assay Kit. Equal amount of protein sample (30 μg) was resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer and denatured for 10 minutes at 95°C. Subsequently, the samples were electrophoresed on 7%–12% SDS-PAGE minigel and transferred onto Immobilon® PVDF membrane at 200 mA for 3 hours, at 4°C. Membranes were probed with indicated primary antibodies overnight at 4°C and then blotted with respective horseradish peroxidase-conjugated secondary anti-mouse or anti-rabbit antibody. Visualization was performed using a Bio-Rad ChemiDocTM XRS system (Bio-Rad Inc., Hercules, CA, USA) with enhanced-chemiluminescence substrate. Protein level was normalized to the matching densitometric value of the internal control, β-actin.
Intracellular level of ROS was measured using 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Invitrogen™; Life Technologies Corp, Carlsbad, CA, USA). Briefly, N2a/APP cells were seeded into black 96-well plates and treated with indicated regimens at different concentrations and different time points. The mean intensity of green fluorescence of 2′,7′-dichlorofluorescein (DCF) was determined by the Synergy H4 Hybrid Microplate Reader, at 485 nm for excitation and 525 nm for detection. Fluorescence was measured every 3 minutes for 45 minutes using the Synergy H4 Hybrid Multi-Mode Microplate Reader. The protein concentration was measured to normalize the intracellular level of ROS.
Determination of autophagy using flow cytometry
To further explore the regulatory effect of Coff, Caff, and Mel on N2a/APP cell death, we determined the autophagy using flow cytometry. N2a/APP cells were plated in 6-well plates (Corning Inc, Corning, NY, USA) at an intensity of 4×105 cells/well. The cells were treated with fresh medium, or Coff/Caff at 10 μM, for 12 hours in the day, followed by Mel at 1, 5, and 10 μM for 12 hours in the night. At the end of the treatment, the cells were trypsinized and centrifuged at 3,000× g for 5 minutes, to pellet the cells. The cells were suspended in 1× assay buffer containing 5% FBS (Enzo Life Sciences Inc.) and collected by centrifugation. Following that, cells were resuspended in 250 μL of phenol red–free culture medium (Invitrogen; Life Technologies Corp) containing 5% FBS. The diluted Cyto-ID® Green stain solution (250 μL) (Enzo Life Sciences Inc.) was added to each sample and mixed well. Cells were incubated for 30 minutes at 37°C, in darkness. After the incubation, cells were washed with 1× assay buffer and resuspended in 500 μL fresh 1× assay buffer. Thereafter, cells were analyzed using the green (FL1) channel of a flow cytometer (BD LSR II Analyzer; BD Biosciences, Franklin Lakes, NJ, USA).
Data were presented as mean ± standard deviation. Comparisons of multiple groups were evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison procedure. P<0.05 was considered statistically different.
Molecular interactions between Caff/Mel and BACE1
Both Caff and Mel are known blockers of BACE1 and reduce Aβ production.37–39 Cleavage of APP at the N-terminus of the Aβ region by BACE1 and at the C-terminus by γ-secretase is the first and key amyloidogenic pathway from the substrate APP to generate Aβ peptides.13,15,21 To explore how Caff and Mel inhibit human BACE1, we first carried out docking experiments using the Discovery Studio program 3.1. After docking Caff or Mel into the active sites of ten BACE1 structures, ten positions were generated for each compound–enzyme interaction. CDOCKER interaction energy ranges from around 17.6-34.6 kcal/mol (Figures 3 and 4, Table 1). Each compound–enzyme complex with the highest CDOCKER interaction energy was selected, and the two-dimensional (2D) and 3D pictures of them were collected. When Caff and Mel were docked into the active sites of the ten selected BACD1 structures, we observed different molecular interactions (Figures 3A–D and 4A–F, Table 1). The data showed that Caff bound to 1FKN and 3DV5 via the formation of a hydrogen bond at the site of Thr72 and Thr232, respectively. Caff formed three hydrogen bonds with 2OHU via Lys238, Lys239, and Lys246, and generated two hydrogen bonds via Gln73 and Thr232. No electrostatic and π-π stacking interactions were observed with Caff and the BACE1 structures.
Table 1 Molecular interactions between Caff and Mel with human BACE1
Mel could be readily docked into the active sites of the ten BACE1 structures (Figure 4A–F). Mel formed two hydrogen bonds with 2OHU via Phe108 and Thr232. It also formed multiple hydrogen bonds with 1W51 (via Gly13), 2P4J (via Gly230 and Thr232), 2VKM (via Asp32, Thr72, and Gly230), 3DV5 (via Asp32 and Gly230), 3U6A (via Gly11, Ser229, and Arg307), and 4FRS (via Asp93, Gly95, and Tyr259). Notably, Mel formed π-π stacking with Tyr71 of 2VKM.
These data demonstrate that both Caff and Mel could readily bind to the active sites of BACE1, mainly via hydrogen bond formation and less commonly, via π-π stacking with the key residue Tyr71. Many of the residues involved in hydrogen bond formation with Caff and Mel are located in the active site of BACE1, and thus, it is not a surprise that both Caff and Mel can act as competitive inhibitors of BACE1.
Effect of Coff or Caff, plus Mel on N2a/APP cell viability
After treatment of N2a/APP cells with Coff or Caff at 10 μM for 12 hours, in combination with Mel at 10 μM for another 12 hours, we measured the cell viability, using the MTT assay. Compared with the vehicle control (medium), Mel at 1 μM alone increased, by 18.4%, cell viability, and Coff (10 μM) plus Mel at 1 or 5 μM increased cell viability, by 25.0% and 35.7%, respectively (P<0.001, by one-way ANOVA) (Figure 5A). Incubation of cells with the combination of Caff with Mel at 1, 5, or 10 μM resulted in a 34.3%, 42.0%, and 21.7% increase in cell viability, respectively (P<0.001). In addition, treatment of cells with 10 μM Caff increased 34.4% in cell viability (P<0.001), but Coff at 10 μM did not affect cell viability (Figure 5B). These results demonstrated that Caff alone or in combination with Mel, and Mel at a low concentration, promoted the proliferation of N2a/APP cells.
Dynamic change of basal extracellular level of Aβ40/42 in N2a/APP cells
N2a/APP cells were treated with G418 to induce Aβ40/42 production prior to the treatment with different chorological regimens. We observed varying extracellular levels of Aβ40/42 over 5 days and a peak at 24 hours (Figure 6). The extracellular level of Aβ40 was 234.3, 1,801.7, and 56.6 pg/μL when cells were treated with G418 for 12 hours, 24 hours, and 5 days, respectively, with a maximum fold change of 31.8. For Aβ42, the maximum fold change was 10.0. These findings demonstrate the dynamic and chronological changes of Aβ40/42 in N2a/APP cells.
Effect of Coff or Caff, plus Mel on the extracellular level of Aβ40/42 in N2a/APP cells
The extracellular level of Aβ40/42 in N2a/APP cells treated with regimen 1
First, we checked the effect of regimen 1 on the extracellular levels of Aβ40/42 in N2a/APP cells. When the cells were incubated with Mel alone at concentrations of 1, 5, or 10 μM for 12 hours, there was a concentration-dependent increase in the extracellular level of Aβ40 in N2a/APP cells. Incubation of cells with 5 or 10 μM Mel elevated the extracellular level of Aβ40 by 1.6- and 2.3-fold, respectively (P<0.001, by one-way ANOVA) (Figure 7A and C). On the other hand, treatment of cells with Coff or Caff alone showed distinct effects on the extracellular level of Aβ40. When N2a/APP cells were treated with Coff at 10 μM alone for 12 hours, the extracellular level of Aβ40 was increased in comparison with the control cells (312.2 vs 234.3 pg/mL) (Figure 7A). When the cells were treated with Caff at 10 μM alone for 12 hours, the extracellular level of Aβ40 was only slightly decreased compared with the control cells (160.1 vs 234.3 pg/mL) (P>0.05) (Figure 7C).
We treated N2a/APP cells with the combination of 10 μM each of Coff/Caff for 12 hours in the day, followed by another 12-hour treatment with Mel at 1, 5, or 10 μM during the night. The extracellular level of Aβ40 was concentration-dependently increased. Compared with the control cells, incubating cells with Coff plus 5 or 10 μM Mel increased the extracellular level of Aβ40 by 1.3- and 2.0-fold, respectively (P<0.001, by one-way ANOVA) (Figure 7A). Treatment of cells with Caff plus 5 or 10 μM Mel resulted in a 2.0- and 4.0-fold increase in the extracellular level of Aβ40, respectively (P<0.001, by one-way ANOVA) (Figure 7C). Incubation of the cells with Caff for 12 hours in the day followed by Mel for 12 hours in the night more significantly increased Aβ40 levels than with Mel alone. In addition, exposure of N2a/APP cells to 5 or 10 μM Mel with Caff increased the extracellular level of Aβ40 1.2- and 1.7-fold, respectively, compared with exposure to Mel alone (P<0.001, by one-way ANOVA) (Figure 7C).
Mel alone significantly increased the extracellular level of Aβ42 in a concentration-dependent manner in N2a/APP cells (Figure 7B and D). Compared with the control cells, incubation of cells with 5 or 10 μM Mel resulted in a 5.8- and 8.0-fold increase in the extracellular Aβ42 level, respectively (195.5 vs 33.9 pg/mL, and 270.4 vs 33.9 pg/mL) (P<0.001, by one-way ANOVA) (Figure 7B). However, treating cells with Coff/Caff alone for 12 hours led to a decrease in the extracellular level of Aβ42 compared with the control cells (26.2/17.0 vs 33.9 pg/mL) (Figure 7B and D). Furthermore, we treated N2a/APP cells with Coff/Caff for 12 hours in the day, followed by Mel for another 12 hours in the night. There was a 3.9- and 4.0-fold increase in the extracellular level of Aβ42 after cells were treated with 10 μM Coff followed by 5 or 10 μM Mel, respectively (P<0.001, by one-way ANOVA) (Figure 7B). Moreover, incubation of cells with 10 μM Caff followed by 5 or 10 μM Mel resulted in a 3.8- and 6.0-fold increase in the extracellular level of Aβ42, respectively (P<0.001, by one-way ANOVA) (Figure 7D). These results demonstrated that Mel alone considerably increased the extracellular levels of Aβ40/42 in N2a/APP cells and that Coff or Caff at relatively high concentration (10 μM) decreased extracellular levels of Aβ40/42 to a greater extent, than did Mel at 1 or 5 μM.
The extracellular level of Aβ40/42 in N2a/APP cells treated with regimen 2
Next, in order to examine the effect of different chorological regimens of Coff/Caff plus Mel, N2a/APP cells were treated with Coff/Caff plus Mel for 24 hours, from 7 am to 7 am the next day (regimen 2). In comparison with the control cells, there was no significant difference in the extracellular level of Aβ40 and Aβ42 when cells were exposed to Coff, Caff, or Mel alone for 24 hours (P>0.05) (Figure 8A–D). However, incubation of cells with 10 μM Coff plus 5 or 10 μM Mel increased by 1.3- and 1.2-fold the extracellular level of Aβ40, respectively (2,359 and 2,173 vs 1,802 pg/mL) (P<0.001, by one-way ANOVA), and by 1.5-fold that of Aβ42 (491.5 vs 314.6 pg/mL) (P<0.001, by one-way ANOVA) (Figure 8A and B). Treating cells with 10 μM Caff plus 5 or 10 μM Mel resulted in a 1.2-fold increase in the extracellular level of Aβ40 (2,224 and 2,117 vs 1,802 pg/mL) (P<0.001, by one-way ANOVA), respectively, and 1.33-fold that of Aβ42 (451.7 vs 314.6 pg/mL) (P<0.001, by one-way ANOVA) (Figure 8C and D).
The extracellular level of Aβ40/42 in N2a/APP cells treated with regimen 3
Furthermore, we treated cells with Coff/Caff with or without Mel combination, for 5 consecutive days with regimen 1 or 2. The data for the changes of the extracellular levels of Aβ40/42 are shown in Figure 9A–H. The extracellular level of Aβ40/42 was lower than that in regimens 1 and 2. Incubation of cells with 10 μM Mel for 12 hours in the night following 10 μM Coff for 12 hours in the day for 5 days significantly reduced, by 17%, the extracellular level of Aβ42 (126.9 vs 149.2 pg/mL) (P<0.001, by one-way ANOVA) (Figure 9B). Treatment of cells with 10 μM Mel for 12 hours in the night following Caff 10 μM for 12 hours in the day for 5 days also significantly decreased, by 8% and 13%, the extracellular level of Aβ40 (52.7 vs 56.9 pg/mL) (P<0.001, by one-way ANOVA) (Figure 9E) and Aβ42, respectively (130.5 vs 149.2 pg/mL) (P<0.05, by one-way ANOVA) (Figure 9F). There were only slight changes in the extracellular Aβ40 level when N2a/APP cells were treated with Caff, Coff, and Mel alone (Figure 9A–H). No significant difference was observed in the extracellular level of Aβ40/42 in N2a/APP cells treated with Coff/Caff plus Mel together for 24 hours over 5 days (Figure 9C, D, G, and H).
Effect of Coff or Caff, plus Mel on the extracellular level of Aβ oligomers in N2a/APP cells
Age-dependent accumulation of Aβ in the brain from “normal brain aging” to AD is a complicated process. It has been proposed that the intracellular level of Aβ oligomers may indicate the progression of AD.58 Therefore, we examined the extracellular level of Aβ oligomers in N2a/APP cells. Our data showed that there was only a slight reduction in the level of Aβ oligomers in N2a/APP cells treated with Coff for 12 hours, followed by Mel for 12 hours (689.8 vs 759.3 pg/mL) (Figure 10A). Incubation of cells with 10 μM Mel for 12 hours in the night following Caff 10 μM for 12 hours in the day reduced, by 22%, the extracellular level of Aβ oligomers in N2a/APP cells (589.5 vs 759.3 pg/mL) (P<0.001, by one-way ANOVA) (Figure 10B). However, there was only a slight reduction of extracellular Aβ oligomer levels in N2a/APP cells treated with Caff alone (658.3 vs 759.3 pg/mL) (P>0.05), whereas Coff elicited an opposite effect on the level of Aβ oligomers (Figure 10A and B).
Coff or Caff, plus Mel did not change the expression levels of cytokines in N2a/APP cells
The buildup of Aβ aggregates in AD is followed by the formation of intracellular neurofibrillary tangles and activation of neuroinflammatory responses.21,59 Mel and Coff/Caff may prevent the cellular damage induced by the exposure of neurons to Aβ, which is associated with neuroinflammation.37 Therefore, we next determined the production of T helper cell (Th)1-related IL-12 and IFN-γ and Th2-related IL-4 and IL-10 in N2a/APP cells. Treatment of N2a/APP cells with Coff or Caff at 10 μM, plus Mel at 1, 5, or 10 μM did not have a significant effect on the levels of these cytokines in N2a/APP cells (P>0.05, by one-way ANOVA) (Figure 11A–H).
Coff or Caff, plus Mel had no effect on autophagy of N2a/APP cells
Both autophagy and apoptosis are basic physiologic processes contributing to the maintenance of cellular homeostasis, involving a sequential set of events, including double membrane formation, elongation, vesicle maturation, and finally, delivery of the targeted materials to the lysosomes.60–62 Autophagy can remove and eliminate damaged organelles to protect cells against cell death. Deregulation of autophagy plays a pivotal role in the etiology and progress of neurodegenerative disorders.49,50 It has been reported that Mel-induced autophagy protected against neuronal apoptosis in rats.63 In order to further unveil the underlying mechanisms for the beneficial effects of Caff, Mel, and Coff on AD, the autophagic effect was examined using flow cytometry. In N2a/APP cells treated with regimen 1, there was only a slight increase in cellular autophagy (Figure 12A–C), and there was no significant alteration in the expression of the autophagy-associated markers Beclin 1 and LC3-I/II (Figure 12D–H). These results suggest that autophagy may play a negligible role in the beneficial effects of Caff, Mel, and Coff on AD.
Coff or Caff, plus Mel reduced oxidative stress in N2a/APP cells via Nrf2 pathway
Oxidative stress has a notorious role in the development and progression of AD;1,21,64,65 oxidative stress interacts with macromolecules, such as DNA and proteins, resulting in cellular dysfunction and eventually leads to cell death. Antioxidation is proposed to be capable of ameliorating the symptoms of AD.66 As such, the antioxidative effects of Coff, Caff, and Mel were examined in N2a/APP cells. Treatment of cells with 10 μM Coff or Caff for 12 hours in the day, combined with 10 μM Mel for 12 hours in the night significantly reduced, by 20.2% and 17.5%, the intracellular levels of ROS, respectively (P<0.05 and P=0.001, respectively, by one-way ANOVA) (Figure 13A and B). Since Nrf2 controls the basal and induced expression of an array of antioxidant response element-dependent genes to regulate the physiological and pathophysiological outcomes of oxidant exposure,67,68 we further determined the effects of Coff/Caff and Mel on its expression in N2a/APP cells. We found that incubation of cells with 10 μM Coff/Caff in the day and 10 μM Mel in the night significantly decreased, by 72.7% and 41.9%, the expression level of Nrf2, respectively (P<0.0001, by one-way ANOVA) (Figure 14A–C). These results suggest that the beneficial effects of Coff/Caff and Mel on AD may be ascribed, at least in part, to antioxidative activity and the involvement of Nrf2-mediated signaling pathway.
Coff or Caff, plus Mel downregulates Wnt3α expression but upregulated β-catenin expression in N2a/APP cells
Dysfunctional Wnt/β-catenin signaling plays an important role in the pathogenesis of AD.69 In the present study, we examined the effect of the combinations of Coff/Caff with Mel on the expression of Wnt3α and β-catenin in N2a/APP cells. The data showed that treatment of cells with Coff/Caff plus 1, 5, or 10 μM Mel decreased, by 20.3%, 29.3%, and 28.0%, and 23.8%, 67.0%, and 77.0%, the expression of Wnt3α, respectively, compared with the control cells (P<0.01 or 0.001, by one-way ANOVA) (Figure 15A–E). There was an increase in the expression of β-catenin when cells were treated with the two combinations. In comparison with the control cells, Coff plus 1, 5, or 10 μM Mel increased, by 9.7%, 53.0%, and 33.3%, respectively, the expression of β-catenin; and Caff plus 5 or 10 μM Mel increased, by 27.9% and 41.3%, respectively, the expression of β-catenin (P<0.001, by one-way ANOVA) (Figure 15A–E). These data clearly demonstrate that Coff/Caff plus Mel or Mel alone concentration-dependently downregulated the expression of Wnt3α/β-catenin in N2a/APP cells, probably contributing to the protective effects of Coff/Caff and Mel on AD.
Coff or Caff, plus Mel inhibited GSK3β, Akt, PI3K p55, and Tau phosphorylation but enhanced PI3K p85 and Erk1/2 phosphorylation in N2a/APP cells
GSK3 is a ubiquitously expressed serine/threonine protein kinase that plays a key role in the pathogenesis of AD.70 GSK3 phosphorylates Tau at serine and threonine, contributing to Aβ production and Aβ-mediated neuronal death.70 Our data showed that the phosphorylation level of GSK3β was significantly reduced, by 17.2% with Coff, and by 33.5% in Caff at 5 μM; and by 61.5% with Coff, and by 52.7% with Caff at 10 μM for 12 hours in the day plus Mel at 10 μM for 12 hours in the night compared with the control cells, respectively (P<0.001, by one-way ANOVA) (Figure 16A–C).
Coff (10 μM) plus 5 or 10 μM Mel elevated 19.6% and 7.0% of the ratio of p-PI3K over PI3K p85, respectively; and Caff (10 μM) plus 1, 5, or 10 μM Mel increased 51.0%, 80.3%, and 80.4% of the ratio of p-PI3K over PI3K p85, respectively (P<0.001, by one-way ANOVA) (Figure 16A–C). Coff at 10 μM plus 1 μM Mel elevated 51.7% of the ratio of p-PI3K over PI3K p55, but this ratio was decreased by 31.4% and 73.1% when the concentration of Mel was increased to 5 or 10 μM, respectively (P<0.001, by one-way ANOVA) (Figure 16A–C). In addition, Caff at 10 μM plus 1 μM Mel increased 47.5% of the ratio of p-PI3K over PI3K p55, but Caff at 10 μM plus 10 μM Mel decreased 23.5% of the ratio (P<0.001, by one-way ANOVA) (Figure 16A–C). However, Caff at 10 μM plus 5 μM Mel only slightly increased the ratio of p-PI3K over PI3K p55 (P>0.05).
Exposure of cells to the combination of Coff/Caff with Mel led to an increase in the phosphorylation of Erk1/2 (P<0.001, by one-way ANOVA) (Figure 16A–C). On the other hand, the phosphorylation level of Akt was significantly reduced, 24.8%/30.1% for Coff/Caff plus Mel at 1 μM; 27.5%/43.6% for Coff/Caff plus Mel at 5 μM; and 42.9%/52.0% for Coff/Caff plus Mel at 10 μM, in N2a/APP cells treated with Coff/Caff at 10 μM for 12 hours in the day plus Mel at 1, 5, or 10 μM for 12 hours in the night compared with the control (P<0.001, by one-way ANOVA) (Figure 16A–C). In addition, incubation with 5 or 10 μM Mel in the night, followed by Coff/Caff at 10 μM in the day significantly reduced 51.5%/53.3% for Coff/Caff plus Mel at 5 μM; and 61.5%/89.2% for Coff/Caff plus Mel at 10 μM of the phosphorylation levels of Tau (P<0.001, by one-way ANOVA) (Figure 16A–C). The same combination significantly inhibited 42.94% (Coff)/52.2% (Caff) of the phosphorylation level of Akt (P<0.01 or 0.001, by one-way ANOVA) (Figure 16A–C). Taken together, these results demonstrated that Coff or Caff plus Mel inhibited GSK3β, Akt, PI3K p55, and Tau phosphorylation but enhanced PI3K p85 and Erk1/2 phosphorylation in N2a/APP cells, probably contributing to the neuroprotective and antiamyloidogenic effect. The reason for the opposing effect of Coff or Caff, plus Mel on PI3K p55 and p85 in N2a/APP cells is unknown, depending on the concentrations of Mel.
Comparison of the neuroprotective and antiamyloidogenicity-enhancing effects between Coff and Caff, plus Mel in N2a/APP cells
Based on above findings, both Coff and Caff chronologically enhanced the antiamyloidogenic activity of Mel in N2a/APP cells. Finally, we compared the beneficial effects of these two combinations (Coff plus Mel vs Caff plus Mel). As shown in Table 2, two combinations showed comparable neuroprotective and antiamyloidogenic effects in N2a/APP cells, but there were some differences in the magnitude of the effects on cell viability, Aβ42 oligomerization, and the phosphorylation of several key regulators. Caff plus Mel significantly increased cell viability but decreased the extracellular level of Aβ oligomers; whereas Coff plus Mel did not exhibit significant effects (Table 2). Caff plus Mel more significantly increased the extracellular level of monomeric Aβ42 than did Coff plus Mel. Compared with the combination of Coff plus Mel, Caff plus Mel showed more potent enhancing effects on the phosphorylation of PI3K and Erk1/2. In addition, Caff plus Mel showed a stronger regulatory effect on Wnt3α than did its counterpart. Overall, Caff had a stronger enhancing effect on the antiamyloidogenic activity of Mel than Coff in N2a/APP cells, suggesting that the Caff in Coff was the main active component that enhanced the antiamyloidogenic activity of Mel and that other components in Coff might compromise the antiamyloidogenic effects of Caff.
AD is characterized by the presence of numerous extracellular plaques and intracellular neurofibrillary tangles, and extracellular Aβ accumulation and Tau hyperphosphorylation and aggregation are the hallmarks of AD.1,15,21 Excessive extracellular Aβ consequently triggers the hyperphosphorylation and aggregation of Tau protein. Inhibition of the production and increase in the clearance of Aβ are the promising strategies to treat AD.1,15,21 In the present study, various chronological regimens of the combination of Caff or Coff plus Mel showed inhibitory effects on the formation of Aβ oligomers, ROS generation, and Tau signaling pathway in N2a/APP cells, which may partially explain their neuroprotective effect in AD mice.
Our data clearly show that the combination of Coff or Caff, with Mel had more potent antiamyloidogenic effects than did a single agent, and Caff showed a larger antiamyloidogenic activity than did Coff in N2a/APP cells. There is epidemiological evidence that supports therapeutic benefits of Coff consumption against development of AD. In a population-based study with follow-up of 21 years, people who drank three to five cups of coffee per day during midlife were observed to have a 65% lower risk of developing AD later in life as compared with those who drank little or no Coff.71 A meta-analysis of pooled epidemiological studies also reported protective effects of Coff consumption against AD.72 On the other hand, decaffeinated coffee may have limited protective effects against AD, implicating the important role of Caff as the major active component against AD. We have previously observed potentiating effect of other unknown Coff components on Caff’s benefits against AD.37 Further studies are required to investigate and compare the effects of caffeinated and decaffeinated Coff on AD, and the dose-response and dose-toxicity relationships of caffeinated Coff and Caff in the treatment of AD should be established.
BACE1 catalyzes the proteolytic cleavage of APP between Met and Asp residues in the sequence stretch of Lys670-Met671-Asp672.18–20 BACE1 is reinternalized from the cell surface to early endosomes and can be recycled back to the cell surface. Considering the long half-life of BACE1 (~9 hours) and the recycling rate, BACE1 moves between the cell surface and the endosomal system many times through the course of its life span.18–20 A double mutant APP with Asn670-Leu671-Asp672 sequence at the cleavage site, found in Swedish patients with early onset AD, is a more efficient substrate in vitro than the wild-type protein and is the cause for the disease in this family. Transgenic mice carrying these mutations showed memory deficit, with a fivefold increase in Aβ40 and a 14-fold increase in Aβ42/43.73 Our molecular docking results showed that Caff could bind to BACE1 via the formation of hydrogen bonds at Thr72, Gln73, Thr232, Lys238, Lys239, and Lys246. Mel could also bind to BACE1 via hydrogen bond formation at Gly11, Gly13, Asp32, Thr72, Asp93, Gly95, Phe108, Ser229, Gly230, Thr232, Tyr259, and Arg307. Furthermore, Mel formed π-π stacking with Tyr71 of BACE1. BACE1 is a monomeric protein, with the catalytic site containing the two aspartate residues, Asp32 and Asp228, located between the N- and C-terminal domains. BACE1 has two aspartic protease active site motifs, DTGS (residues 93–96) and DSGT (residues 289–292), and mutation of either aspartic acid renders the enzyme inactive. The active site is covered by a flexible antiparallel β hairpin between Val67 and Glu77 (commonly known as the “flap”) that forms a large portion of the binding pocket and offers shielding from the solvent to facilitate efficient enzymatic catalysis.74 BACE1 becomes activated within the late Golgi compartments and endosomes/lysosomes. The acidic conditions optimal for the enzyme (pH of 4.5–6) indicate that an inhibitor containing a basic amine with a pKa of ≥6.0 would show a high affinity. Tyr71 is a key residue in the flap, which adopts a conformation complementary to the shape and nature of the substrates/inhibitors bound in the active site.74 The changing position of the flap relative to the catalytic dyad provides a means for the substrates/inhibitors to get access into the active site.74 The conformation of BACE1 is defined as “closed” in the inhibitor-bound form when the Tyr71 side chain hydroxyl on the flap is within hydrogen bonding distance to the nitrogen of the Trp76 indole side chain (with a distance of 3.3 Å), but the hydrogen bond in the β-strands between Tyr71 and Gly74 is not formed, which physically separates the S1 and S2’ subsites. Also, the side chain of Arg128 occupies a space between Arg128 and Tyr198 in the inactive form. In contrast, the conformation of BACE1 is defined as “open” when the flap moves away from the catalytic Asp, the hydrogen bond between the flap residues Tyr71 and Trp76 is not formed, and Tyr71 does not occupy the position between the S1 and S2’ subsites.74 In the open form of BACE1, Tyr71 may adopt a unique orientation to form a hydrogen bond between the backbone carbonyl of Lys107, and the hydrogen bond in the β-strands between Tyr71 and Gly74 is formed.75 As such, conformational change in the flap must take place upon binding of the substrate/inhibitor to the active site and may participate kinetically in substrate binding in the closed conformation and product release in the open conformation. Both Caff and Mel are known BACE1 inhibitors.37–39 BACE1 belongs to the pepsin family of the aspartyl protease superfamily and has the most sequence identity with BACE2 (52%), cathepsin D (29%), pepsin (27%), cathepsin E (27%), and renin (24%).18–20 To date, a number of BACE1 inhibitors have been developed and tested at the preclinical stage; several of them, including LY2886721, E-2609, MK-8931, RG-7129, HPP-854, and AZD-3839, have been evaluated in Phase I studies. The open form of the BACE1 enzyme appears to offer a more drug-like binding cavity than does the closed form of the enzyme. The inhibitors that target the open-form BACE1 are of low molecular weight; high binding efficiency; low polar surface area with improved metabolic stability, P-glycoprotein efflux, and oral bioavailability, and Aβ-lowering activity, in animal models and in human clinical trials.20,76
The monomeric Aβ (molecular weight ~4 kDa) is generated mainly in neurons from APP (molecular weight ~120 kDa) via sequential scission by β- and γ-secretase.13,17,77,78 Aβ is a heterogeneous mixture of peptides with distinct solubility, stability, and biological and toxic properties. γ-Secretase cleaves APP at different positions, giving rise to a variety of peptides, of which Aβ43, Aβ42, Aβ40, Aβ38, and Aβ37 can be detected in cell culture and body fluids.13,17,77,78 The heterogeneity of Aβ is enhanced by other enzymes, such as aminopeptidases, glutaminyl cyclase, isomerases, and protein kinases, resulting in a mix of more than 20 Aβ peptides that all participate in putative Aβ functions in the normal brain and in oligomerization and fibrillization in AD.13,17,77,78 Aβ40 is continuously and abundantly produced in both the normal and AD brain, whereas other Aβ peptides are formed at lower levels. Aβ40 and Aβ42 are present in plaques, and increased Aβ40 and/or Aβ42 levels have been implicated in the pathogenesis of AD.1,15,21,79 Aβ can self-assemble into fibrils, protofibrils, and globular oligomer structures. Amyloid plaques might exist in equilibrium with oligomeric forms of Aβ, consisting of cross-β-sheet units of Aβ peptides that are arranged to form amyloid fibrils. The monomeric form of Aβ has no cytotoxicity toward neurons, whereas Aβ oligomers are neurotoxic, resulting in cellular dysfunction and cell death.77–80 Aβ oligomers may be metastable intermediates on the pathway to an insoluble, cross-β-sheet-based fiber. Aβ monomers, oligomers, and fibrils exist in a complex equilibrium, sensitive to numerous external factors. Loss of function and decrease in the number of neurons eventually impair cognitive function and lead to AD.60 There is evidence that Aβ oligomers are important neurotoxic forms, which are composed of two to 32 monomers.77–80 The neurotoxicity of Aβ oligomers is associated with the loss of synapses, a process that leads to hippocampal long-term potentiation decrease. This impairing effect of Aβ oligomers could underlie the cognitive impairment associated with AD.81,82 In the present study, we found that treatment of N2a/APP cells with Coff or Caff plus Mel increased the extracellular levels of the monomeric form of Aβ40/42 but decreased the extracellular level of Aβ oligomers, suggesting that the combination therapy suppressed Aβ oligomerization and thus increased the level of nontoxic monomers of Aβ peptides. Coff or Caff plus Mel combinations appeared to affect the equilibrium between Aβ monomers and oligomers, favoring the existence of Aβ monomers.
Intervention in the Aβ aggregation process has been considered as a practical approach to stop or slow the progression of AD. It has been demonstrated that Mel directly interacts with Aβ, and prevents its aggregation and inhibits the progressive formation of β sheet and/or amyloid fibrils.83,84 Mel may accelerate the conversion of β sheets into random coils by disrupting the imidazole–carboxylate salt bridges, which prevent Aβ fibrillogenesis and aggregation. It therefore blocks the formation of the secondary β sheet conformation. Moreover, Mel facilitates the clearance of Aβ peptides via increasing proteolytic degradation. On the other hand, it has been shown that Coff and Caff can attenuate cognitive impairment and improve memory function, in AD and in other chronic neurodegenerative disorders, through the regulatory effect on mitochondrial function and oxidative stress.85
Previous studies on Coff, Caff, and Mel have shown beneficial effects in AD.86,87 However, there was no report on the combined use of Coff/Caff with Mel with chronological considerations. In our study, we treated A2a/APP cells with Coff/Caff in the day, followed with Mel in the night, which is consistent with rhythm of Mel secretion in human pineal gland. We therefore speculated that N2a/APP cells may have their own circadian rhythms, leading to different effects on cells treated with the same drug at the same concentration with different chronological regimens. To test this speculation, we treated N2a/APP cells with three different chronological regimens and found that the antiamyloidogenic effects of the Coff/Caff plus Mel was regimen-dependent, suggesting the importance of chronotherapy in AD treatment. A most remarkable and synergistic/additive effect on reduced extracellular Aβ40/42 level was observed in N2a/APP cells treated with regimen 1, where cells were treated with Caff/Coff in day time, followed by Mel in night time, whereas this effect was smaller or disappeared when regimens 2 and 3 were used. These findings support the pathophysiological and therapeutic implications of circadian rhythms in AD. Previous studies have shown that Caff/Coff administration in day time benefited AD or dementia in mice or humans.88–90 It has also been shown that there is a circadian clock in N2a cells and that treatments were only effective at specific circadian times.91 Abnormal and disturbed circadian rhythms are common in AD.30,46 Chronotherapeutic approaches aimed at bolstering weakened circadian rhythms in AD produce beneficial outcomes. A double-blind study of Mel in AD patients revealed improvements in cognition as well as decreasing nocturnal activity and increased nocturnal sleep.92 Further studies are needed to optimize the chronotherapy for AD using Coff/Caff and Mel.
Oxidative stress and impaired energy metabolism play an important role in the pathogenesis of AD.1,21,58,59 Cerebral tissues are particularly vulnerable to oxidative damage, due to its high oxygen consumption, low content of antioxidants, and high content of polyunsaturated fatty acids of neuronal membranes. Aβ itself and phosphorylated Tau cause oxidative damage to neurons.1,21,58,59 Mitochondrial dysfunction in AD could cause an increased generation of free radicals, and damage major cellular macromolecules, including DNA, proteins, and lipids. Dysregulation of Nrf2 plays a role in the development and pathogenesis of AD, and Nrf2 can attenuate Aβ-induced neurotoxicity and Tau phosphorylation.93–95 The neuroprotective and antiamyloidogenic activities of Coff, Caff, and Mel may be attributed to their antioxidative effects through the involvement of Nrf2 signaling pathway. Previous studies showed that Coff activated the Nrf2-mediated signaling pathway to exert its neuroprotective effect.96 Nrf2 is a nuclear transcription factor, playing a pivotal role in the regulation of oxidative stress by modulating the transcription of antioxidant response elements.68 The effect of Coff on Nrf2 activation indicates that Coff may reduce oxidative stress through Nrf2-mediated signaling pathways. In addition, it has been reported that Mel possesses a strong antioxidative effect.97,98 In the present study, we found that the combination of Coff/Caff plus Mel in regimen 1 significantly reduced the oxidative stress in N2a/APP cells, contributing to the neuroprotective and antiamyloidogenic effect.
It has been reported that inhibition of GSK3 can exhibit profound neuroprotective effects, which have been proposed as promising and practical therapeutic targets for the treatment of AD.48 GSK3 is regarded as a critical molecular link between senile plaques and neurofibrillary tangles. It can trigger the hyperphosphorylation of Tau, resulting in an exaggerated progressive condition of AD. Moreover, GSK3 can be inhibited by Akt in the Akt/GSK3β/Tau pathway.99 It has been shown that the regulatory effect of Mel on the Akt/GSK3β/Tau pathway is, at least in part, responsible for is beneficial effect.100 Wang et al101 showed the consensus change in the Akt/Gsk3β/Tau pathway in N2a cells. In agreement with the previous studies, our findings showed that phosphorylation levels of Akt, GSK3β, and Tau were decreased in N2a/APP cells treated with the combination of Coff/Caff plus Mel. Notably, our studies provided evidence for the stronger effect of the combination of Caff in day time, followed by Mel in night time on inhibiting Tau hyperphosphorylation. Moreover, the combinations of Coff/Caff plus Mel negatively regulated Wnt/β-catenin signaling, which may contribute to the attenuation in the Akt/GSK3β/Tau signaling in N2a/APP cells. Intriguingly, the combination of Coff/Caff plus Mel showed a promoting effect on the phosphorylation of PI3K and Erk1/2 in N2a/APP cells. PI3K and Erk1/2 play a critical role in the regulation of cell growth, cell migration, cell survival, and cell death. All the regulating effects of Coff/Caff plus Mel on above important signaling molecules may contribute to proproliferative, neuroprotective, and antiamyloidogenic activities in N2a/APP cells.
Inflammation and dysregulated autophagy have a causal role in the pathogenesis of AD.102–105 However, our data did not support the concept that Coff/Caff plus Mel produced antiamyloidogenic effect through modulation of these two processes in N2a/APP cells. In other studies, Mel has been shown to have potent anti-inflammatory effects, via suppression of cytokine and nitric oxide production.106–108 Caff also has a potent modulating effect on inflammation, through adenosine receptor and other pathways.109,110 Both Caff and Mel are potent inducers of autophagy in different animal and disease models.63,111,112 Therefore, further studies are needed to explore the effects and the underlying mechanisms of Coff, Caff, and Mel on inflammation and autophagy.
In summary, Coff and Caff chronologically enhanced the antiamyloidogenic activity of Mel through suppression of Aβ oligomerization and modulation of the Akt/GSK3β/Tau pathway in N2a/APP cells (Figure 17). We have observed that the antiamyloidogenic effects of Coff/Caff plus Mel were more potent than were Coff, Caff, or Mel alone. Since Caff is mainly metabolized to paraxanthine, theobromine, and theophylline, and Mel is principally metabolized to 6-hydroxymelatonin, which is further conjugated with sulfate, these metabolites may contribute to the antiamyloidogenic action. Further studies are warranted to dissect the role of adenosine and melatonin receptors and other molecules for the neuroprotective and antiamyloidogenic activities of Coff or Caff plus Mel. These data will provide strong rationales for the Phase I trials on the combination of Coff or Caff, plus Mel in AD patients, when chronotherapy is taken into consideration.
The authors appreciate the support from the College of Pharmacy and Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
The authors report no conflicts of interest in this work.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011;377(9770):1019–1031.
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329–344.
Gilbert T, Herbst M. Alzheimer’s disease: charting the crossroads between neurology and psychology. J Neurol Neurosurg Psychiatry. 2014;85(2):133–134.
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640–651.
Ferri CP, Prince M, Brayne C, et al; Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117.
Fargo K, Bleiler L. Alzheimer’s Association report. Alzheimers Dement. 2014;10(2):e47–e92.
Chan KY, Wang W, Wu JJ, et al; Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet. 2013;381(9882):2016–2023.
Weuve J, Hebert LE, Scherr PA, Evans DA. Deaths in the United States among persons with Alzheimer’s disease (2010–2050). Alzheimers Dement. 2014;10(2):e40–e46.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
Gulland A. Number of people with dementia will reach 65.7 million by 2030, says report. BMJ. 2012;344:e2604.
Wimo A, Jönsson L, Bond J, Prince M, Winblad B; Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1–11.e3.
Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement. 2010;6(2):98–103.
Ittner LM, Götz J. Amyloid-β and Tau – a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):65–72.
Haass C, Mandelkow E. Fyn-Tau-amyloid: a toxic triad. Cell. 2010;142(3):356–358.
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204–1222.
Selkoe DJ. SnapShot: pathobiology of Alzheimer’s disease. Cell. 2013;154(2):468–468.e1.
Bloom GS. Amyloid-β and Tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–508.
Kandalepas PC, Vassar R. Identification and biology of β-secretase. J Neurochem. 2012;120 Suppl 1:S55–S61.
Wang H, Li R, Shen Y. β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol Sci. 2013;34(4):215–225.
Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014;13(3):319–329.
Karran E, Hardy J. Antiamyloid therapy for Alzheimer’s disease – are we on the right road? N Engl J Med. 2014;370(4):377–378.
Aguzzi A, Gitler AD. A template for new drugs against Alzheimer’s disease. Cell. 2013;154(6):1182–1184.
Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer’s disease: rational strategies and recent progress. Annu Rev Med. 2013;64:367–383.
Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr. 2011;51(4):363–373.
Biessels GJ. Caffeine, diabetes, cognition, and dementia. J Alzheimers Dis. 2010;20 Suppl 1:S143–S150.
Barrenetxe J, Delagrange P, Martinez JA. Physiological and metabolic functions of melatonin. J Physiol Biochem. 2004;60(1):61–72.
Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014;56(4):371–381.
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):101–110.
Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab. 1999;84(1):323–327.
Naismith SL, Hickie IB, Terpening Z, et al. Circadian misalignment and sleep disruption in mild cognitive impairment. J Alzheimers Dis. 2014;38(4):857–866.
Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease. J Nutr Health Aging. 2014;18(4):383–392.
Arendash GW, Cao C. Caffeine and coffee as therapeutics against Alzheimer’s disease. J Alzheimers Dis. 2010;20 Suppl 1:S117–S126.
Arendash GW, Schleif W, Rezai-Zadeh K, et al. Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience. 2006;142(4):941–952.
Canas PM, Porciúncula LO, Cunha GM, et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci. 2009;29(47):14741–14751.
Dragicevic N, Bradshaw PC, Mamcarz M, et al. Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer’s transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit? Neuroscience. 2011;185:135–149.
Cao C, Loewenstein DA, Lin X, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis. 2012;30(3):559–572.
Cao C, Wang L, Lin X, et al. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer’s mice. J Alzheimers Dis. 2011;25(2):323–335.
He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. Curr Neuropharmacol. 2010;8(3):211–217.
Lahiri DK. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J Pineal Res. 1999;26(3):137–146.
Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–549.
Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007;47:593–628.
Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418(6901):935–941.
Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol. 2013;13(3):190–198.
Hermida RC, Ayala DE, Smolensky MH, et al. Chronotherapy improves blood pressure control and reduces vascular risk in CKD. Nat Rev Nephrol. 2013;9(6):358–368.
Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9(12):886–896.
Coogan AN, Schutová B, Husung S, et al. The circadian system in Alzheimer’s disease: disturbances, mechanisms, and opportunities. Biol Psychiatry. 2013;74(5):333–339.
Kaur G, Phillips C, Wong K, Saini B. Timing is important in medication administration: a timely review of chronotherapy research. Int J Clin Pharm. 2013;35(3):344–358.
Llorens-Martín M, Jurado J, Hernández F, Avila J. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014;7:46.
Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2014;112:24–49.
Tan CC, Yu JT, Tan MS, Jiang T, Zhu XC, Tan L. Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy. Neurobiol Aging. 2014;35(5):941–957.
Wang ZX, Sun J, Howell CE, et al. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundam Clin Pharmacol. 2014;28(5):551–582.
Liu YH, Mo SL, Bi HC, et al. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica. 2011;41(4):259–280.
Mo SL, Liu WF, Chen Y, et al. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap). Comb Chem High Throughput Screen. 2012;15(1):36–80.
Mo SL, Liu WF, Li CG, et al. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening. Curr Pharm Biotechnol. 2012;13(9):1640–1704.
Yang LP, Zhou ZW, Chen XW, et al. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. Xenobiotica. 2012;42(3):238–255.
Ma QL, Lim GP, Harris-White ME, et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and Tau phosphorylation in vivo and in vitro. J Neurosci Res. 2006;83(3):374–384.
Kayed R, Head E, Sarsoza F, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.
Saido TC. Metabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease. Proc Jpn Acad Ser B Phys Biol Sci. 2013;89(7):321–339.
Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774.
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–241.
Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med. 2013;19(7):428–446.
Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717–1721.
Chen J, Wang L, Wu C, et al. Melatonin-enhanced autophagy protects against neural apoptosis via a mitochondrial pathway in early brain injury following a subarachnoid hemorrhage. J Pineal Res. 2014;56(1):12–19.
Swomley AM, Förster S, Keeney JT, et al. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta. 2014;1842(8):1248–1257.
Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta. 2014;1842(8):1240–1247.
Aliev G, Obrenovich ME, Reddy VP, et al. Antioxidant Therapy in Alzheimer’s Disease: Theory and Practice. Mini Rev Med Chem. 2008;8(13):1395–1406.
Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 2013;34(6):340–346.
Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
Purro SA, Galli S, Salinas PC. Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. J Mol Cell Biol. 2014;6(1):75–80.
Hernandez F, Lucas JJ, Avila J. GSK3 and Tau: two convergence points in Alzheimer’s disease. J Alzheimers Dis. 2013;33 Suppl 1: S141–S144.
Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis. 2009;16(1):85–91.
Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis. 2010;20 Suppl 1:S187–S204.
Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99–102.
Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production. Mol Cell Biol. 2008;28(11):3663–3671.
Hong L, Tang J. Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. Biochemistry. 2004;43(16):4689–4695.
Yuan J, Venkatraman S, Zheng Y, McKeever BM, Dillard LW, Singh SB. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2013;56(11):4156–4180.
Wilcox KC, Lacor PN, Pitt J, Klein WL. Aβ oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol. 2011;31(6):939–948.
Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012;15(3):349–357.
Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387–398.
Klein WL. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease? J Alzheimers Dis. 2013;33 Suppl 1:S49–S65.
Barghorn S, Nimmrich V, Striebinger A, et al. Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem. 2005;95(3):834–847.
Gong Y, Chang L, Viola KL, et al. Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100(18):10417–10422.
Poeggeler B, Miravalle L, Zagorski MG, et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry. 2001;40(49):14995–15001.
Masilamoni JG, Jesudason EP, Dhandayuthapani S, et al. The neuroprotective role of melatonin against amyloid beta peptide injected mice. Free Radic Res. 2008;42(7):661–673.
Cunha RA, Agostinho PM. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis. 2010;20 Suppl 1:S95–S116.
Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ. Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol Sin. 2004;25(4):447–451.
Wang XC, Zhang YC, Chatterjie N, Grundke-Iqbal I, Iqbal K, Wang JZ. Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells. Neurochem Res. 2008;33(6):1138–1144.
Flaten V, Laurent C, Coelho JE, et al. From epidemiology to pathophysiology: what about caffeine in Alzheimer’s disease? Biochem Soc Trans. 2014;42(2):587–592.
Laurent C, Eddarkaoui S, Derisbourg M, et al. Beneficial effects of caffeine in a transgenic model of Alzheimer’s disease-like Tau pathology. Neurobiol Aging. 2014;35(9):2079–2090.
Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and etiology of Alzheimer’s disease: from genetic to non-genetic factors. Curr Alzheimer Res. 2013;10(8):852–867.
Repouskou A, Sourlingas TG, Sekeri-Pataryas KE, Prombona A. The circadian expression of c-MYC is modulated by the histone deacetylase inhibitor trichostatin A in synchronized murine neuroblastoma cells. Chronobiol Int. 2010;27(4):722–741.
Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70(4):334–341.
Kanninen K, Malm TM, Jyrkkänen HK, et al. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci. 2008;39(3):302–313.
Jo C, Gundemir S, Pritchard S, Jin YN, Rahman I, Johnson GV. Nrf2 reduces levels of phosphorylated Tau protein by inducing autophagy adaptor protein NDP52. Nat Commun. 2014;5:3496.
Kärkkäinen V, Pomeshchik Y, Savchenko E, et al. Nrf2 regulates neurogenesis and protects neural progenitor cells against Aβ toxicity. Stem Cells. 2014;32(7):1904–1916.
Trinh K, Andrews L, Krause J, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson’s disease through an NRF2-dependent mechanism. J Neurosci. 2010;30(16):5525–5532.
Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19(9):1410–1418.
Vielma JR, Bonilla E, Chacín-Bonilla L, Mora M, Medina-Leendertz S, Bravo Y. Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: a review. Acta Trop. 2014;137:31–38.
Zhang X, Shi M, Ye R, et al. Ginsenoside Rd attenuates Tau protein phosphorylation via the PI3K/AKT/GSK-3β pathway after transient forebrain ischemia. Neurochem Res. 2014;39(7):1363–1373.
Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer’s disease. Int J Mol Sci. 2013;14(7):14575–14593.
Wang Y, Liu W, He X, Zhou F. Parkinson’s disease-associated DJ-1 mutations increase abnormal phosphorylation of Tau protein through Akt/GSK-3β pathways. J Mol Neurosci. 2013;51(3):911–918.
Lynch MA. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease. Immunology. 2014;141(3):292–301.
Ułamek-Kozioł M, Furmaga-Jabłońska W, Januszewski S, et al. Neuronal autophagy: self-eating or self-cannibalism in Alzheimer’s disease. Neurochem Res. 2013;38(9):1769–1773.
Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–997.
Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer’s disease. Alzheimers Res Ther. 2013;5(5):53.
Vilar A, de Lemos L, Patraca I, et al. Melatonin suppresses nitric oxide production in glial cultures by pro-inflammatory cytokines through p38 MAPK inhibition. Free Radic Res. 2014;48(2):119–128.
Aparicio-Soto M, Alarcón-de-la-Lastra C, Cárdeno A, Sánchez-Fidalgo S, Sanchez-Hidalgo M. Melatonin modulates microsomal PGE synthase 1 and NF-E2-related factor-2-regulated antioxidant enzyme expression in LPS-induced murine peritoneal macrophages. Br J Pharmacol. 2014;171(1):134–144.
Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model. J Crit Care. 2014;29(1):184.e9–e184.e13.
Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J. 2013;41(4):966–973.
Gołembiowska K, Wardas J, Noworyta-Sokołowska K, Kamiska K, Górska A. Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson’s disease. Neurotox Res. 2013;24(1):29–40.
Saiki S, Sasazawa Y, Imamichi Y, et al. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy. 2011;7(2):176–187.
Sinha RA, Farah BL, Singh BK, et al. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology. 2014;59(4):1366–1380.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]